The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
F Pietrini, U Albert, A Ballerini, P Calò… - Neuropsychiatric …, 2019 - Taylor & Francis
Schizophrenia is a chronic syndrome involving different clinical dimensions, and causes
significant disability with a negative impact on the quality of life of patients and their …
significant disability with a negative impact on the quality of life of patients and their …
A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia
A Forbes, M Hobart, J Ouyang, L Shi… - International Journal …, 2018 - academic.oup.com
Background Brexpiprazole is a serotonin–dopamine activity modulator with efficacy in acute
schizophrenia and relapse prevention. The aim of this Phase 3, multicenter study was to …
schizophrenia and relapse prevention. The aim of this Phase 3, multicenter study was to …
Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
F Pinna, L Deriu, E Diana, V Perra… - Annals of general …, 2015 - Springer
Aims This study aimed to compare the performance of Positive and Negative Syndrome
Scale (PANSS) symptom severity criteria established by the Remission in Schizophrenia …
Scale (PANSS) symptom severity criteria established by the Remission in Schizophrenia …
Insight and recovery in schizophrenic patients
D Cannavò, G Minutolo, E Battaglia… - International journal of …, 2016 - Taylor & Francis
Objective: To investigate the correlation between insight and recovery in schizophrenic
patients according to criteria for both symptomatic and functional remission. Methods …
patients according to criteria for both symptomatic and functional remission. Methods …
Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once …
N Li, Y Feng, H Lu, SL Cai, J Zhuo, T Si… - … Disease and Treatment, 2018 - Taylor & Francis
Background Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and
functional remission in patients with schizophrenia. This post hoc analysis aimed to identify …
functional remission in patients with schizophrenia. This post hoc analysis aimed to identify …
[HTML][HTML] Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
D Naber, RA Baker, A Eramo, C Forray, K Hansen… - Schizophrenia …, 2018 - Elsevier
Objective To evaluate long-term safety and effectiveness of continued treatment with
aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia. Methods …
aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia. Methods …
[HTML][HTML] Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
F Pinna, M Bosia, R Cavallaro, B Carpiniello… - Schizophrenia Research …, 2014 - Elsevier
Criteria developed by the Remission in Schizophrenia Working Group (RSWG), based upon
8 core symptoms of PANSS, are generally used for evaluation of Remission. However, some …
8 core symptoms of PANSS, are generally used for evaluation of Remission. However, some …
Occupational balance and emotional regulation in people with and without serious mental illness
DM Romero-Ayuso… - Canadian journal of …, 2024 - journals.sagepub.com
Background. Serious mental illness affects daily functioning, including occupational
balance. Purpose. This study aims to compare occupational balance and emotional …
balance. Purpose. This study aims to compare occupational balance and emotional …
Regulación emocional y funcionamiento social en pacientes con esquizofrenia
D Romero-Ayuso, JG Arenas - Revista Interamericana de …, 2020 - journal.sipsych.org
Introduction: Social disability is present in more than 50% of patients with schizophrenia
after clinical remission. How emotional processing differs between patients with high and …
after clinical remission. How emotional processing differs between patients with high and …
Dimensions and course of clinical recovery in schizophrenia and related disorders
B Carpiniello, F Pinna, M Manchia… - Recovery and Major Mental …, 2022 - Springer
Recovery is considered the optimal outcome of treatments in schizophrenia and related
psychoses. In general, two clear-cut parallel visions of recovery have been developed, one …
psychoses. In general, two clear-cut parallel visions of recovery have been developed, one …